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Aims There are limited data on coronary obstruction following transcatheter valve-in-valve (ViV) implantation inside
failed aortic bioprostheses. The objectives of this study were to determine the incidence, predictors, and clinical
outcomes of coronary obstruction in transcatheter ViV procedures.
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Methods
and results
A total of 1612 aortic procedures from the Valve-in-Valve International Data (VIVID) Registry were evaluated.
Data were subject to centralized blinded corelab computed tomography (CT) analysis in a subset of patients. The
virtual transcatheter valve to coronary ostium distance (VTC) was determined. A total of 37 patients (2.3%) had
clinically evident coronary obstruction. Baseline clinical characteristics in the coronary obstruction patients were
similar to controls. Coronary obstruction was more common in stented bioprostheses with externally mounted
leaflets or stentless bioprostheses than in stented with internally mounted leaflets bioprostheses (6.1% vs. 3.7% vs.
0.8%, respectively; P < 0.001). CT measurements were obtained in 20 (54%) and 90 (5.4%) of patients with and
without coronary obstruction, respectively. VTC distance was shorter in coronary obstruction patients in relation
to controls (3.24 ± 2.22 vs. 6.30 ± 2.34, respectively; P < 0.001). Using multivariable analysis, the use of a stentless
or stented bioprosthesis with externally mounted leaflets [odds ratio (OR): 7.67; 95% confidence interval (CI):
3.14–18.7; P < 0.001] associated with coronary obstruction for the global population. In a second model with CT
data, a shorter VTC distance predicted this complication (OR: 0.22 per 1 mm increase; 95% CI: 0.09–0.51;
P < 0.001), with an optimal cut-off level of 4 mm (area under the curve: 0.943; P < 0.001). Coronary obstruction
was associated with a high 30-day mortality (52.9% vs. 3.9% in the controls, respectively; P < 0.001).
...................................................................................................................................................................................................
Conclusion Coronary obstruction following aortic ViV procedures is a life-threatening complication that occurred more frequently
in patients with prior stentless or stented bioprostheses with externally mounted leaflets and in those with a short VTC.
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Introduction
Coronary obstruction is a life-threatening complication of transcatheter
aortic valve replacement (TAVR), and it is commonly secondary to dis-
placement of a valve leaflet towards the coronary ostia.1,2 We have
recently conducted a multicentre registry on coronary obstruction
showing that this is a rare (incidence < 1%) but life-threatening compli-
cation following TAVR. Specific anatomic factors such as low-lying cor-
onary ostium and shallow sinus of Valsalva (SOV) were associated with
this complication.1,2 Also, coronary obstruction was much more fre-
quent during TAVR for degenerative bioprosthetic valves (‘valve-in-
valve’—ViV).2 However, the number of ViV cases was limited, preclud-
ing a thorough evaluation of this complication in such patients.
Transcatheter heart valve (THV) implantation inside failed aortic
surgically implanted bioprosthetic valves represents an appealing less
invasive alternative to reoperation, with growing indication worldwide.
Of note, the Valve-in-Valve International Data (VIVID) Registry, which
is the largest evaluation of ViV to date, has also revealed a much higher
rate of coronary obstruction as compared with native aortic valves
(four-fold greater), in accordance to the aforementioned reports.3–5
Nonetheless, prior studies presented limited number of ViV cases suf-
fering this complication without any comparison against a control
group, preventing the determination of its exact incidence, in function
of the different surgically implanted bioprosthetic valves, associated fac-
tors and outcomes. The objectives of the present study were therefore
to evaluate the baseline characteristics, predictive factors, and clinical
outcomes of coronary obstruction as a complication of TAVR in
patients with prior surgically implanted aortic bioprosthesis.
Methods
Registry design
The VIVID Registry is a global data collection of ViV procedures, including
different THV devices and valve positions.4 Since 2010, the registry
prospectively collects data from centres in Europe, North America, South
America, Africa, Oceania, and the Middle East. Data collection is performed
using dedicated case report forms. In the following analysis, all of the cases
from April 2007 until May 2016 were included, though patients undergoing
ViV in non-aortic positions were excluded. No restriction to the THV or
aortic bioprosthesis type and size were considered. The patients present-
ing coronary obstruction were compared with those without coronary
obstruction and served as controls. Inconsistencies were resolved directly
with local investigators and on-site data monitoring. All patients gave writ-
ten informed consent to the transcatheter aortic ViV procedures.
Definitions
All information on clinical presentation, diagnosis, and treatment of the
coronary obstruction complication, as well as 30-day and late clinical out-
comes were entered. The clinical events were defined according to the
VARC-2 criteria.6 The mechanism of bioprosthetic valve degeneration
(i.e. regurgitation, stenosis, or combined) was evaluated using criteria set
by previous guidelines.7,8 Patients with at least a moderate degree of both
stenosis and regurgitation were included in the combined group. Other
patients were categorized according to the primary mechanism of degen-
eration, either stenosis or regurgitation.
Computed tomography
Centralized core laboratory assessment of the computed tomography
(CT) from 20 patients with coronary obstruction and 90 consecutive con-
trols from 2 centres were performed by two experienced operators
blinded to all clinical results (St. Paul’s Hospital, Vancouver, Canada). The
main baseline bioprosthetic valve characteristics of the patients in the con-
trol group with and without CT data are shown in Supplementary material
online, Table S1. In addition, the main baseline characteristics between
patients with CT data pre-TAVR with and without coronary obstruction
are shown in Supplementary material online, Table S2. The CT measure-
ments included the surgical frame mean diameter and area, coronaries
height in relation to aortic annulus, aortic annulus diameter and area, SOV
width, and the diameter of the sinotubular junction. The coronary artery
heights were measured relative to basal ring of the prosthetic valve.
Likewise, we sought to validate the previously described Vancouver
2 H.B. Ribeiro et al.
Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehx455/4082639
by Universitaetsbibliothek Bern user
on 12 February 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
method5,9 for predicting the risk of coronary occlusion as determined by
the distance between a virtual transcatheter valve, at a size of the
implanted device, towards each coronary ostium in both groups (VTC;
Figure 1). Essentially, the VTC is obtained by identifying the basal ring plane
and the geometric centre of the surgical valve. Then, a virtual cylinder with
the estimated nominal size of the THV (i.e. a 26mm THV leads to a cylin-
der with the same height of the THV and a 26 mm diameter) is placed in
the middle of the basal ring. The centres of the basal ring and of the cylin-
der are aligned. Finally, the horizontal distance between the edge of the
cylinder and the ostia of the coronary arteries is measured with a caliper
measurement tool of the CT imaging software. The anticipated area of the
THV was estimated by the circle area formula: pR2, where the radius (R) is
obtained dividing the diameter of the device by 2. Therefore, in the case of
self-expanding devices such as the CoreValve the worst-case scenario was
used.9 Thus, for both the Sapien XT and CoreValve the following areas
were used: 20mm (314 mm2), 23mm (415 mm2), 26mm (531 mm2),
29 mm (661mm2), and 31mm (754 mm2). For the Sapien 3 device, the fol-
lowing values were used: 20mm (309 mm2), 23mm (409 mm2), 26mm
(519 mm2), 29mm (649 mm2).9
Statistical analysis
Categorical variables are reported as n (%) and continuous variables are
expressed as mean (standard deviation) or median [interquartile range
(IQR)] depending on variable distribution. Group comparisons were ana-
lysed using the Student t-test or Wilcoxon rank sum test. The v2 test and
the Fisher exact test were performed for categorical variables, and post
hoc analysis used the Bonferroni correction. Time-to-event curve was cal-
culated using the Kaplan–Meier method. To further determine the inde-
pendent predictors of coronary obstruction after VIV procedures a
multivariable analysis was performed, using logistic regression. Variables
with P < 0.10 in the univariable analysis were further examined in a step-
wise model. The initial selection of variables included the whole cohort of
1612 patients and the following variables were included in the multivari-
able model: type of bioprosthetic valve, STS-PROM, balloon post-dilata-
tion, and prior coronary artery bypass grafting (CABG). A second model
including only the subgroup of patients with CT data was performed and
the following variables were included in the model: type of bioprosthetic
valve, VTC distance, and SOV mean diameter. The results of the multi-
variable analysis are presented as odds ratio (OR) with 95% confidence
interval (CI). Correlations between CT parameters were assessed by
Pearson’s coefficient. All analyses were conducted using the statistical
package SPSS 22 (IBM Inc., Armonk, NY, USA).
Results
Of 1612 patients who underwent a ViV procedure in 135 centres
worldwide, a total of 37 cases (2.3%) of symptomatic coronary
obstruction occurred following THV implantation. The incidence of
coronary obstruction according to the type of surgically implanted
bioprostheses is shown in Figure 2, while its distribution with respect
to the type of transcatheter valve, approach, and mechanism of bio-
prosthetic surgical valve failure is shown in Supplementary material
online, Figure S1. A higher incidence of this complication was only
seen with regards to the type of bioprosthesis. The main baseline
characteristics of the study population, according to the occurrence
of coronary obstruction, are shown in Table 1. Patients who suffered
symptomatic coronary obstruction presented similar baseline clinical
characteristics with respect to controls, apart from the differences in
the type of surgically implanted bioprostheses. In addition, CABG
was less frequent in those with coronary obstruction in relation to
controls (P = 0.05). The main procedural and 30-day outcomes are
shown in Table 2. The procedural variables were similar between
both groups, except for a trend towards a higher rate of post-
dilatation in the coronary obstruction group (22.2% vs. 12.7%,
respectively; P = 0.07). At 30 days, death rate was much higher in this
group vs. controls (48.6% vs. 3.7%; P < 0.001).
Computed tomography data
Pre-TAVR CT data were available in 20 of the 37 patients with coro-
nary obstruction (54%). CT data of the patients with coronary
obstruction in relation to the control group are shown in Table 3.
Patients with coronary obstruction exhibited a smaller SOV diameter
(27.44 ± 4.05 vs. 32.55 ± 3.98; P < 0.001). In addition, although the
coronary artery heights with respect to the annulus were similar
between both groups, the VTC distance to the left and right coronary
arteries [left coronary artery (LCA) and right coronary artery (RCA),
respectively] were much shorter in the coronary obstruction group
in relation to controls (P < 0.001 for both).
Predictors of coronary obstruction
The main predictors of coronary obstruction are shown in Table 4.
Using multivariable analysis, the use of a stentless or stented
Figure 1 Multidetector computed tomography evaluation pre-TAVR showing the measurement of the distance between a virtual transcatheter
ring at a size of the implanted device at the level of each coronary ostium (VTC) with a case example of short VTC for both coronary arteries.
(A) Virtual ring; (B) VTC to the right coronary artery ostium (RCA); (C) VTC to the left coronary artery ostium (LCA); (D) Effaced sinus of Valsalva.
Coronary obstruction in valve-in-valve TAVR 3
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..bioprosthesis with externally mounted leaflets (OR: 7.67; 95% CI: 3.14–
18.7; P< 0.001) was an independent predictor of coronary obstruction
in the overall population. Likewise, when including only the patients
with a CT pre-TAVR, the multivariable analysis showed that the VTC
was the only predictor of coronary obstruction (OR: 0.22 per 1 mm
increase; 95% CI 0.09–0.51; P < 0.001), even after adjusting for SOV
width. In addition, the SOV width presented significant collinearity with
the VTC (R2 = 0.688, P < 0.001; Supplementary material online, Figure
S2). A VTC cut-off value of 4 mm best identified those patients at higher
risk for coronary obstruction (area under the curve: 0.943 [0.893–
0.991]; sensitivity = 85%, specificity = 89%; P < 0.001). The distribution
of the VTC relative to the LCA and RCA ostia is shown in Figure 3 for
both groups.
Clinical presentation and management
Data on clinical presentation and management of coronary obstruc-
tion were available for 36 patients (97% of the population), as shown
in Table 5. Coronary obstruction occurred at the ostium of the LCA
in most cases (91.7%) either alone or in association with RCA occlu-
sion, and the diagnosis was made by coronary angiography in all but
one patient. Coronary obstruction was related to the displacement
of bioprosthetic valve leaflet towards the coronary ostium in all
patients, and occurred most frequently immediately after valve
implantation (58.3%). Still, it occurred within days following the
procedure in 36.1% of the patients (76.9% of the time with self-
expandable devices). Most cases (58.3%) presented with severe
persistent hypotension or electrocardiographic (ECG) changes
(52.8%), mainly driven by ST-segment deviation and ventricular
arrhythmias.
Coronary revascularization with percutaneous coronary interven-
tion (PCI) was not attempted in eight patients (22.2%). One patient
died within the few minutes following a complete left coronary
obstruction with insufficient time for any coronary revascularization
attempt; in four patients the occlusion occurred within the hours
following the procedure with no time for PCI; one patient went
directly to urgent CABG; in one patient the obstruction occurred
after pre-dilatation, with temporary occlusion of the LMS and subse-
quent abandoning of the procedure; and in one patient a reposition-
able valve allowed the relief of the obstruction by retrieving the
device (Lotus valve). PCI was attempted in 28 patients (77.8%), and it
was successful (residual stenosis < 20% and TIMI flow 3) in 64.3% of
attempted procedures. Revascularization failures by PCI were mainly
due to wire crossing failure (50%) or cannulation failure (30%). A total
of three patients underwent urgent coronary artery bypass graft, and
in two patients occurring after PCI failure. A total of 13 patients
(36.1%) required haemodynamic support.
Procedural death occurred in 8 patients (22.2%), and among those
patients who survived the procedure 10 additional patients died
within 30 days, all of them related to the periprocedural complica-
tions, leading to a 30-day mortality rate of 48.6% (18 patients).
Among the patients with PCI failures, 80% died within 30 days. In
patients with coronary obstruction, the echocardiographic data
showed a mean residual gradient of 11.1 ± 5.2 mmHg, aortic valve
area of 1.46 ± 0.47 cm2, with no patients presenting with more than
mild aortic regurgitation. These results were similar as compared
with the controls. As shown in the Kaplan–Meier curve the 1-year
survival rate was 47.8% in the coronary obstruction group (Figure 4).
At a median follow-up of 460 days (IQR 361–1014.25) among the
survivors of the coronary obstruction group, the mean left ventricu-
lar ejection fraction was 55.9% ± 7.5 and 78.6% of the patients were
in New York Heart Association class <_ 2.
Discussion
The main findings of the present study evaluating coronary obstruc-
tion as a complication of TAVR, in patients with prior surgically
implanted aortic bioprosthesis, were as follows: (i) coronary
Figure 2 Incidence of coronary obstruction following valve-in-valve procedures according to surgical bioprosthesis type.
4 H.B. Ribeiro et al.
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Table 1 Baseline characteristics of patients undergoing aortic valve-in-valve
Controls
(n 5 1575)
Coronary
obstruction
(n 5 37)
P-value
Clinical variables
Age (years) 77.8 ± 9.3 76.7 ± 12.2 0.50
Patient height (cm) 167.5 ± 10 164.6 ± 9.4 0.10
Patient weight (kg) 75.3 ± 16.5 75.4 ± 14.5 0.97
Body mass index (kg/m2) 27 ± 11.7 27.8 ± 4.8 0.68
Female sex 662/1573 (42.1) 20/37 (54.1) 0.15
NYHA class 0.91
I– II 157/1534 (10.2) 4/37 (10.8)
III– IV 1377/1534 (89.8) 33/37 (89.2)
Diabetes mellitus 402/1572 (25.6) 10/37 (27.0) 0.84
Number of previous cardiac surgeries 0.66
1 1259/1483 (84.9) 34/37 (91.9)
2 198/1483 (13.4) 3/37 (8.1)
3 22/1483 (1.5) 0 (0)
4 4/1483 (0.3) 0 (0)
Prior CABG 387/1541 (25.1) 4/37 (10.8) 0.05
Cerebrovascular disease 216/1571 (13.7) 4/37 (10.8) 0.61
Peripheral vascular disease 335/1570 (21.3) 5/36 (13.9) 0.28
Renal failure (eGFR <60 mL/min) 774/1547 (50.0) 17/36 (47.2) 0.74
LVEF (%) 52.1 ± 13.1 51.8 ± 13.3 0.88
LogEuroSCORE (%) 29.1 ± 16.9 36.1 ± 23.1 0.08
EuroSCORE 2 (%) 14.5 ± 8.6 16.1 ± 11 0.37
STS-PROM score (%) 9.5 ± 8.4 12.1 ± 10.9 0.07
Bioprosthetic valve
Time since last SAVR (years) 9 (6–13) 8 (5–12) 0.39
Type <0.001
Stented with internally mounted leafletsa 954/1532 (62.3) 7/37 (18.9)
Stented with externally mounted leafletsb 313/1532 (20.4) 12/37 (32.4)
Stentlessc 265/1532 (17.3) 18/37 (48.6)
Mean label size (mm) 23.3 ± 2.2 23 ± 1.8 0.40
Distribution of label sizes 0.45
<_21 mm 427/1506 (28.4) 13/35 (37.1)
>21 and <25 mm 559/1506 (37.1) 10/35 (28.6)
>_25 mm 520/1506 (34.5) 12/35 (34.3)
Mean true ID (mm) 20.1 ± 2.4 20.8 ± 2.9 0.20
Mechanism of failure 0.17
Regurgitation 415/1490 (27.9) 14/36 (38.9)
Stenosis 589/1490 (39.5) 9/36 (25.0)
Both 486/1490 (32.6) 13/36 (36.1)
Mean aortic gradient (mmHg) 35.5 ± 17.6 35.1 ± 23.1 0.93
Aortic valve area (cm2) 0.98 ± 0.65 1.13 ± 0.89 0.24
Values are expressed as n (%) or mean (±SD).
NYHA, New York Heart Association; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration ratio; LVEF, left ventricular ejection fraction; logEuroSCORE,
logistic EuroSCORE predicted risk of mortality; STS-PROM, Society of Thoracic Surgeons predicted risk of mortality; SAVR, surgical aortic valve replacement; ID: internal diam-
eter; SD, standard deviation.
aAspire, Biocor, Carpentier Edwards, Epic, Hancock, Labcor, Magna, Mosaic, Soprano.
bMitroflow, Trifecta.
cCryolife O’Brien, Freedom, Freestyle, Toronto SPV.
Coronary obstruction in valve-in-valve TAVR 5
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..obstruction following aortic ViV procedures is a life-threatening com-
plication with high procedural and short-term mortality; (ii) coronary
obstruction occurred more frequently in patients with prior stentless
or stented with externally mounted leaflets bioprostheses; (iii) short
VTC as evaluated by CT (<4 mm) predicted this complication; and
(iv) clinical presentation included most likely persistent severe hypo-
tension and ST-segment changes, and although PCI may be
attempted in the majority of the patients, haemodynamic support
and conversion to open heart surgery were still required in a signifi-
cant proportion of them, with more than half dying within 30 days fol-
lowing TAVR.
Coronary obstruction and valve-in-valve:
incidence and associated factors
The risks of coronary obstruction following TAVR have been
stressed since the first experimental and clinical experiences,10–12
and it was first reported in the context of ViV procedures in
2011.13 Since then, the reported incidence of coronary obstruc-
tion has been higher during ViV procedures, reaching up to 3.5%
of the patients,3 as opposed to systematically <1% in native aortic
valves.1,2 In the present study, including a large series of ViV-
TAVR, we have shown an incidence of 2.3%, supporting the
....................................................................................................................................................................................................................
Table 2 Main procedural characteristics and short-term results
Controls
(n 5 1575)
Coronary obstruction
(n 5 37)
P-value
Procedural variables
Approach 0.77
Transfemoral 1164/1574 (74) 30/37 (81.1)
Transapical 339/1574 (21.5) 5/37 (13.5)
Transaortic 24/1574 (1.5) 1/37 (2.7)
Trans-subclavian 40/1574 (2.5) 1/37 (2.7)
Other 7/1574 (0.4) 0 (0)
Mean THV size (mm) 24.7 ± 2.1 24.6 ± 2.1 0.80
Distribution of THV sizes 0.79
20 mm 16/1546 (1) 1/36 (2.8)
23 mm 793/1546 (51.3) 18/36 (50)
25/26 mm 586/1546 (37.9) 13/36 (36.1)
27/29 mm 133/1546 (8.6) 4/36 (11.1)
31/34 mm 18/1546 (1.2) 0/36 (0)
Ratio of true ID to THV size 0.82 ± 0.08 0.84 ± 0.09 0.14
Prosthesis type 0.85
Balloon-expandable valve (Sapien/Sapien XT) 544/1574 (34.6) 12/37 (32.4)
Self-expandable valve (CoreValve) 780/1574 (49.6) 20/37 (54.1)
Othersa 250/1574 (15.9) 5/37 (13.5)
Balloon pre-dilatation 357/1555 (23) 8/36 (22.2) 0.92
Balloon post-dilatation 182/1485 (12.3) 8/36 (22.2) 0.07
Need 2nd valve 67/1570 (4.3) 2/37 (5.4) 0.74
30-day results
Death 56/1508 (3.7) 18/37 (48.6) <0.001
Major stroke 22/1566 (1.4) 0 (0) 0.48
Major or life-threatening bleeding 91/1528 (6) 4/36 (11.1) 0.20
Vascular complication 0.18
Major 45/1571 (2.9) 3/37 (8.1)
Minor 98/1571 (6.2) 2/37 (5.4)
Echocardiographic results
Maximal gradient (mmHg) 29.2 ± 14.7 21.6 ± 9.8 0.03
Mean gradient (mmHg) 16.3 ± 8.9 11.1 ± 5.2 <0.001
Aortic valve area (cm2) 1.47 ± 0.49 1.46 ± 0.47 0.94
Aortic regurgitation > mild 91/1463 (6.2) 0 (0) 0.19
LVEF (%) 51.6 ± 11.9 48.2 ± 14.5 0.17
Values are expressed as n (%) or mean (±SD).
THV, transcatheter heart valve. Other abbreviations as in Table 1.
aOther valves included: SAPIEN 3, Evolut, Lotus, JenaValve and Portico.
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..presence of certain surgically implanted valves (stentless or
stented bioprostheses with externally mounted leaflets) as poten-
tial risk factors for this complication.1,2,5
The mechanisms underlying coronary obstruction following ViV
appear to be displacement of the bioprosthetic leaflet towards the
coronary ostium in all patients, and no cases of coronary obstruction
related to the struts of the transcatheter valve frame or to the cuff/
leaflets of the transcatheter valve itself were noted in the present
study.1,2 Also, according to prior smaller ViV studies,4 this complica-
tion was more frequent with stented bioprostheses with externally
mounted leaflets, and also with stentless bioprostheses, representing
up to 80% of the obstructions. In externally mounted bioprosthe-
ses, the relatively long leaflets outside the stent, in comparison with
internally mounted leaflets, may be the causative factor for a higher
rate of coronary obstruction.13 Furthermore, the stentless biopros-
theses are usually implanted in a supra-annular position, resulting in a
shorter distance of the coronary ostia take-off in relation to the valve
leaflets, which in association with lack of stent posts, may facilitate the
interaction of the prosthetic leaflet and the coronary ostia.
Unlike prior studies in native aortic valves, no association of the
transcatheter valve type with this complication was detected.1,2 Also,
we have noticed a higher rate of post-dilatation in the coronary
obstruction group, even though this factor was not retained in the
multivariable analysis. Of note, in a recent in vitro study with the
SAPIEN XT THV implanted inside a Trifecta bioprosthesis (stented
with externally mounted leaflet), the use of an undersized THV
implantation successfully avoided coronary flow obstruction.14
Future studies also may consider post-dilatation and relative THV siz-
ing as predictors of coronary occlusion.
In addition, our study is the first to confirm the Vancouver method
of the VTC distance by CT as an important factor related to this
complication.5,9 Also, we were able to define a cut-off associated
with an increased risk of this severe complication (<4 mm; area under
the curve: 0.943). Importantly, in the present study up to 90% (18/
....................................................................................................................................................................................................................
Table 3 Computed tomography data, according to the occurrence of coronary obstruction following transcatheter
aortic valve replacement
Controls
(n 5 90)
Coronary obstruction
(n 5 20)
P-value
Surgical frame mean diameter (mm) 20.6 ± 2.6 21.1 ± 3.3 0.39
Surgical frame area (cm2) 3.37 ± 0.85 3.59 ± 1.25 0.35
SOV width (mm) 32.55 ± 3.98 27.44 ± 4.05 <0.001
STJ height (mm) 19.25 ± 3.97 20.01 ± 7.58 0.52
LCA height to annulus distance (mm) 9.69 ± 4.12 9.48 ± 2.67 0.82
RCA height to annulus distance (mm) 11.17 ± 4.33 11.97 ± 2.52 0.43
LCA originates above the posts 5/86 (5.8) 0 (0) 0.27
RCA originate above the posts 14/86 (16.3) 0 (0) 0.05
VTC to LCA (mm) 6.30 ± 2.34 3.24 ± 2.22 <0.001
VTC to RCA (mm) 6.08 ± 2.43 3.90 ± 3.49 0.002
Values are expressed as mean ±SD.
SOV, sinus of Valsalva; STJ, sinotubular junction; LCA, left coronary artery; RCA, right coronary artery; VTC, distance between a virtual transcatheter ring at a size of the
implanted device at the level of each coronary ostium; SD, standard deviation.
....................................................................................................................................................................................................................
Table 4 Predictors of coronary obstruction following valve-in-valve procedures
Univariable Multivariable model
OR (95% CI) P-value OR (95% CI) P-value
Model for the overall population (n = 1612)
CABG to the left system 0.36 (0.13–1.03) 0.056 0.38 (0.13– 1.09) 0.07
STS-PROM 1.03 (0.99–1.06) 0.068 1.02 (0.99– 1.05) 0.21
Post-dilatation 2.05 (0.92–4.56) 0.080 1.82 (0.8– 4.14) 0.15
Stented with external mounted leaflet or stentless bioprosthesis 7.07 (3.09–16.2) <0.001 7.67 (3.14– 18.7) <0.001
Model for the computed tomography cohort (n = 110)
VTCa 0.18 (0.08– 0.39) <0.001 0.22 (0.09– 0.51) <0.001
Sinus of Valsalva mean diameter 0.70 (0.58– 0.83) <0.001 0.95 (0.72– 1.25) 0.71
Stented with external mounted leaflet or stentless bioprosthesis 4.90 (1.51– 15.9) 0.008 4.30 (0.85– 21.7) 0.08
Abbreviations as in Tables 1 and 3.
aPer unit increase.
Coronary obstruction in valve-in-valve TAVR 7
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20) of the patients with CT data pre-TAVR and coronary obstruction
had a VTC distance < 4 mm, supporting its inclusion in the workup
prior to aortic ViV procedures. The SOV width was an important fac-
tor related to this complication in native valves. However, in the
present study after adjusting for the VTC, this factor was not retained
in the multivariable analysis. Most likely, the SOV presented a signifi-
cant collinearity with respect to the VTC, and also it does not
account for the occasional canted position of a slightly tilted and non-
coaxial surgically implanted prosthesis.5
Collectively, in those patients considered at high risk for coronary
obstruction, it is reasonable to suggest the implementation of addi-
tional security measures during ViV procedures, such as coronary
protection with a guidewire and an undeployed stent in the coronary
artery.1,2,15,16 Finally, the use of a transcatheter valve that can be
repositioned or retrieved in case of coronary obstruction following
valve implantation should probably be recommended in such cases,
although the occurrence of late coronary obstruction in up to one-
third of the patients may mitigate such benefits.
Clinical presentation and management of
coronary obstruction following valve-in-
valve
The majority of the patients presented with persistent severe hypo-
tension and ST-segment changes immediately after valve implanta-
tion. This clinical presentation is explained by the fact that the LCA
was obstructed in the majority of the patients either alone or in asso-
ciation with RCA occlusion, and this is in accordance with prior stud-
ies in the context of native aortic valves.1,2 Of note, the presence of
persistent severe hypotension following valve implantation, and espe-
cially in conjunction with ECG changes, should prompt aortography
and/or echocardiography to evaluate coronary flow abnormalities or
new segmental abnormalities. In those cases where a pre-emptive
coronary wire protection with or without stent placement were per-
formed, prompt selective coronary injection may confirm the diagno-
sis and further expedite treatment with PCI.16
In the present study, PCI was attempted in the majority of the
patients, and was successful in most of them. Still, in up to one-third
of patients, urgent CABG or mechanical support was required.
Overall, the 30-day mortality rate was close to half of the patients,
and it reached 80% of those patients with unsuccessful PCI. This even
higher mortality rates as compared with native aortic valves (41%)2,3
underscores that these procedures should be performed in highly
experienced centres with surgical capabilities, in order to potentially
restore coronary flow by CABG in case of PCI failure. Also, as this
complication may have delayed onset in a significant proportion of
patients, especially with self-expandable devices (77% among late
Figure 3 Distribution of distance between a virtual transcatheter
ring at a size of the implanted device at the level of the coronary
artery (VTC) in controls and in patients suffering coronary obstruc-
tion of the left coronary artery (LCA) and right coronary artery
(RCA). The optimal cut-off level of 4 mm best predicts this compli-
cation for left coronary obstruction (area under the curve: 0.943;
P < 0.001). All cases of RCA obstruction also occurred with con-
comitant LCA occlusion.
Table 5 Clinical presentation and management of
coronary obstruction following valve-in-valve (n 5 36)
Obstructed coronary artery
Left coronary artery 26/36 (72.2)
Right coronary artery 3/36 (8.3)
Both 7/36 (19.4)
Timing
After balloon valvuloplasty 1/36 (2.8)
After valve implantation 21/36 (58.3)
After balloon post-dilatation 1/36 (2.8)
Within 24 h following TAVR 8/36 (22.2)
More than 24 h following TAVR 5/36 (13.9)
Clinical presentation
Severe persistent hypotension 21/36 (58.3)
ECG changes 19/36 (52.8)
ST-segment elevation 13/19 (68.4)
Ventricular fibrillation 4/19 (21.1)
Atrial fibrillation 2/19 (10.5)
Stenosis severity
Partial occlusion 20/35 (57.1)
Complete occlusion 15/35 (42.9)
Treatment
PCI attempted 28/36 (77.8)
Successful 18/28 (64.3)
Unsuccessful 10/28 (35.7)
Coronary cannulation failure 3/10 (30.0)
Wire crossing failure 5/10 (50.0)
Stent could not be advanced 1/10 (10.0)
Stent implanted but no flow 1/10 (10.0)
Type of stent
Bare-metal stent 6/18 (33.3)
Drug-eluting stent 10/18 (55.6)
Both stents 2/18 (11.1)
Urgent CABG 3/31 (9.7)
Need for haemodynamic support 13/36 (36.1)
Values are expressed as n (%) or mean (±SD).
TAVR, transcatheter aortic valve replacement; ECG, electrocardiographic; PCI,
percutaneous coronary intervention. Other abbreviations as in Table 1.
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obstructions) that tend to further expand following TAVR, such
patients should probably be monitored longer in the intensive care
unit.
Study limitations
Coronary angiograms leading to the diagnosis of coronary obstruc-
tion were analysed by the investigators of each centre. Pre-TAVR CT
data were available in only part of the coronary obstruction patients
and in a control group of 90 patients. While this represents only part
of the entire cohort of the study, this is to date the largest pre-TAVR
CT analysis in the context of aortic ViV procedures that was also
entirely subject to centralized core laboratory analysis.1,17–21 The
number of patients undergoing TAVR with the new retrievable and
repositionable delivery systems was small, and precluded the per-
formance a separate analysis of such THVs in the context of ViV pro-
cedures. Finally, future studies with a larger number of patients will
have to confirm the VTC as significant factor related to coronary
obstruction in ViV, and also further evaluate the cut-offs proposed
herein.
In conclusion, the present study evaluating coronary obstruction
as a complication of ViV procedures has shown that this is a rare but
life-threatening complication that occurs more frequently in patients
with stentless and stented bioprostheses with externally mounted
leaflets, and in those with a short VTC. Despite successful treatment
(mainly PCI) in most cases, haemodynamic support and conversion
to open heart surgery were still required in a large proportion of
patients, highlighting that such high-risk TAVR procedures should
probably be performed in very experienced centres.
Supplementary material
Supplementary material is available at European Heart Journal online.
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